Chemistry:SBI-115
From HandWiki
SBI-115 is an experimental drug which acts as a potent and selective antagonist for the G protein-coupled bile acid receptor (GPBAR1/TGR5). It is used for studying the function of this receptor, and has been found to show beneficial effects in animal models of polycystic liver disease as well as some forms of cancer.[1][2][3][4][5]
References
- ↑ "TGR5 contributes to hepatic cystogenesis in rodents with polycystic liver diseases through cyclic adenosine monophosphate/Gαs signaling". Hepatology (Baltimore, Md.) 66 (4): 1197–1218. October 2017. doi:10.1002/hep.29284. PMID 28543567.
- ↑ "Investigation of the potential role of TGR5 in pancreatic cancer by a comprehensive molecular experiments and the liquid chromatography mass spectrometry (LC-MS) based metabolomics". Discover Oncology 13 (1). June 2022. doi:10.1007/s12672-022-00504-2. PMID 35689739.
- ↑ "Bifidobacterium pseudocatenulatum-Mediated Bile Acid Metabolism to Prevent Rheumatoid Arthritis via the Gut-Joint Axis". Nutrients 15 (2): 255. January 2023. doi:10.3390/nu15020255. PMID 36678126.
- ↑ "Taurocholic acid ameliorates hypertension through the activation of TGR5 in the hypothalamic paraventricular nucleus". Food & Function 15 (9): 5088–5102. May 2024. doi:10.1039/d4fo00808a. PMID 38666497.
- ↑ "Activation of TGR5 in the injured nerve site according to a prevention protocol mitigates partial sciatic nerve ligation-induced neuropathic pain by alleviating neuroinflammation". Pain 166 (6): 1296–1313. June 2025. doi:10.1097/j.pain.0000000000003460. PMID 39450924.
 |  |
